- Home
- LGCL vs VRCA Comparison
LGCL vs VRCA Comparison
Compare LGCL & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCL
- VRCA
- Stock Information
- Founded
- LGCL 2009
- VRCA 2013
- Country
- LGCL China
- VRCA United States
- Employees
- LGCL N/A
- VRCA N/A
- Industry
- LGCL
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- LGCL
- VRCA Health Care
- Exchange
- LGCL NYSE
- VRCA Nasdaq
- Market Cap
- LGCL 39.7M
- VRCA 43.0M
- IPO Year
- LGCL 2024
- VRCA 2018
- Fundamental
- Price
- LGCL $0.55
- VRCA $0.53
- Analyst Decision
- LGCL
- VRCA Hold
- Analyst Count
- LGCL 0
- VRCA 5
- Target Price
- LGCL N/A
- VRCA $6.00
- AVG Volume (30 Days)
- LGCL 73.9K
- VRCA 266.5K
- Earning Date
- LGCL 01-01-0001
- VRCA 05-13-2025
- Dividend Yield
- LGCL N/A
- VRCA N/A
- EPS Growth
- LGCL N/A
- VRCA N/A
- EPS
- LGCL 0.07
- VRCA N/A
- Revenue
- LGCL $145,690,427.00
- VRCA $7,179,000.00
- Revenue This Year
- LGCL N/A
- VRCA $127.85
- Revenue Next Year
- LGCL N/A
- VRCA $105.09
- P/E Ratio
- LGCL $8.03
- VRCA N/A
- Revenue Growth
- LGCL N/A
- VRCA N/A
- 52 Week Low
- LGCL $0.28
- VRCA $0.38
- 52 Week High
- LGCL $3.31
- VRCA $9.36
- Technical
- Relative Strength Index (RSI)
- LGCL N/A
- VRCA 48.29
- Support Level
- LGCL N/A
- VRCA $0.49
- Resistance Level
- LGCL N/A
- VRCA $0.73
- Average True Range (ATR)
- LGCL 0.00
- VRCA 0.07
- MACD
- LGCL 0.00
- VRCA -0.01
- Stochastic Oscillator
- LGCL 0.00
- VRCA 23.50
About LGCL LUCAS GC LIMITED
Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.